Tafenoquine gets U.S. Food and Drug Administration (FDA) Breakthrough Therapy designation News Tafenoquine gets U.S. Food and Drug Administration (FDA) Breakthrough Therapy designation GlaxoSmithKline (GSK) and Medicines for Malaria Venture (MMV) announced on December 20, 2013 that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for tafenoquine.
Tafenoquine is an investigational 8-aminoquinoline derivative for the treatment and relapse prevention of Plasmodium vivax malaria. It is not yet approved or licensed for use anywhere in the world.
Breakthrough Therapy designation is a new FDA programme aimed at accelerating the development and review times of drugs for serious or life-threatening conditions like malaria.
The Breakthrough Therapy designation was granted based on the results from an international, multicentre, randomised Phase II clinical trial in more than 300 patients with uncomplicated P. vivax malaria. The detailed results were published online in The Lancet in December 2013.
More information about the results of the Phase II clinical trial on tafenoquine published in The Lancet is available here: http://www.sciencedirect.com/science/article/pii/S0140673613625684. The article will be freely available on Malaria Nexus soon.
Posted by seibertneurolyme (Member # 6416) on :
Great news -- maybe finally a new a med for babesia.